AAM Report: Generics and Biosimilars Generate $408 Billion in 2022

A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.

Related Keywords

Texas ,United States ,West Virginia ,Kentucky ,Georgia ,Wyoming ,Louisiana ,Vermont ,California ,New York ,Alaska ,Indiana ,American ,America ,David Gaugh ,Association For Accessible Medicines ,American Journal ,Accessible Medicines ,Biosimilar Medicines Savings Report ,Hatch Waxman Act ,Biosimilars ,Generics ,Medicare ,Savings ,